RecruitingNCT05500612
MRI Hypoxia Study for Glioblastoma Multiforme (GBM) Radiation Therapy
Magnetic Resonance Imaging of Hypoxia for Radiation Treatment Guidance in Glioblastoma Multiforme (MANGO)
Sponsor
University of Sydney
Enrollment
20 participants
Start Date
Aug 14, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This study is designed to evaluate the role of Oxygen Enhanced (OE) Magnetic resonance imaging (MRI) and Blood Oxygenation Level Dependent (BOLD) MRI in detecting regions of hypoxic tumour and to evaluate their use as imaging methods to selectively deliver targeted radiotherapy to regions of aggressive disease.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Suspected high-grade glioma (HGG) / glioblastoma multiforme (WHO grade IV) at initial radiological examination
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2
- Available for scanning on two separate days
Exclusion Criteria9
- Women lactating, pregnant or of childbearing potential who are not willing to avoid pregnancy during the study
- Patients with a history of severe renal disease(s) (eGFR <20) that cannot tolerate gadolinium chelate contrast agents.
- Geographically remote patients unable to agree to imaging schedule
- Patients who have received anti - vascular endothelial growth factor (anti-VEGF) monoclonal antibody therapy the 3 months prior to recruitment
- Patients with a history of psychological illness or condition such as to interfere with the patient's ability to understand the requirements of the study.
- Patients with significant cardiac or pulmonary disease including cardiac arrythmias or Chronic Obstructive Pulmonary Disease (COPD) that are unable to tolerate high flow O2 for oxygen contrast.
- Patients taking carbonic anhydrase inhibitors (Acetazolamide)
- History of glaucoma
- Any implant, foreign body, 3 Tesla (3T) MRI incompatible device, or other contraindication to MRI imaging.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05500612
Related Trials
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
NCT074161881 location
IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma
NCT053535301 location
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
NCT068144962 locations
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
NCT039113883 locations
Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma
NCT052817311 location